Preview

Атеротромбоз

Расширенный поиск

СОВРЕМЕННЫЕ ПОДХОДЫ К СТРАТИФИКАЦИИ РИСКА БОЛЬНЫХ, ПОДВЕРГАЕМЫХ ПЛАНОВЫМ ЧРЕСКОЖНЫМ КОРОНАРНЫМ ВМЕШАТЕЛЬСТВАМ

https://doi.org/10.21518/2307-1109-2016-2-65-80

Полный текст:

Аннотация

Обзор посвящен оценке прогноза и стратификации риска больных, подвергаемых плановым чрескожным коронарным вмешательствам. Обсуждаются современные шкалы, основанные на различных клинических и ангиографических показателях, и возможность их применения в рутинной практике. Рассмотрены вопросы персонификации антитромбоцитарной терапии на основании оценки риска тромбозов и кровотечений. 

Об авторах

А. Л. Комаров
НИИ кардиологии; РКНПК МЗ РФ
Россия
д.м.н.


Е. С. Московкина
НИИ кардиологии; РКНПК МЗ РФ
Россия


Список литературы

1. Mohr FW, Morice MC, Kappetein AP et al. Coronary artery bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet, 2013, 381(9867): 629–638.

2. http: //www.syntaxscore.com.

3. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg, 1999, 16(1): 9–13.

4. Peterson ED, Dai D, DeLong ER et al. Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. J Am Coll Cardiol, 2010, 55(18): 1923–1932.

5. Byrne А, Serruys P W, Baumbach А et al. Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. Eur Heart J, 2015 Oct 7, 36(38): 2608-2620.

6. 2014 ESC/EACTS Guidelines on myocardial revascularization The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J, 2014 Oct 1, 35(37): 2541-2619.

7. Гуськова Е.В., Панченко Е.П., Комаров А.Л., Добровольский А.Б., Самко А.Н. Остаточная реактивность тромбоцитов к АДФ и риск кровотечений у больных стабильной ИБС, получающих двойную антитромбоцитарную терапию в связи с плановым чрескожным коронарным вмешательством. Российский кардиологический журнал, 2015, 3 (119): 35-42.

8. Комаров А.Л., Илющенко Т.А., Шахматова О.О., Деев А.Д., Самко А.Н., Панченко Е.П. Сравнительная эффективность консервативного и инвазивного лечения больных со стабильной формой ишемической болезни сердца (по результатам пятилетнего проспективного наблюдения). Кардиология, 2012, 52 (8), 4-14.

9. Urban Р, Abizaid А, Banning А et al. Stent Thrombosis and Bleeding Complications After Implantation of Sirolimus-Eluting Coronary Stents in an Unselected Worldwide Population. A Report From the e-SELECT (Multi-Center Post-Market Surveillance) Registry. J Am Coll Cardiol, 2011, 57: 1445–1454.

10. Naidu SS, Polin GM, Selzer F et al. Outcome of Percutaneous Coronary Intervention in Unstable Angina Pectoris Versus Stable Angina Pectoris in Two Different Time Periods. Am J Cardiol, 2006, 98: 447–452.

11. Sedlis SP, Hartigan PM, Teo KK, Maron DJ, Spertus JA, Mancini GB, Kostuk W, Chaitman BR, Berman D, Lorin JD, Dada M, Weintraub WS, Boden WE, COURAGE. Trial Investigators. Effect of PCI on longterm survival in patients with stable ischemic heart disease. N Engl J Med, 2015, 373: 1937–1946.

12. Hueb W, Lopes N, Gersh BJ, Soares PR, Ribeiro EE, Pereira AC, Favarato D, Rocha AS, Hueb AC, Ramires JA. Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation, 2010, 122(10): 949–957.

13. Hochman JS, Lamas GA, Buller CE, Dzavik V, Reynolds HR, Abramsky SJ, Forman S, RuzylloW, Maggioni AP, White H, Sadowski Z, Carvalho AC, Rankin JM, Renkin JP, Steg PG, Mascette AM, Sopko G, Pfisterer ME, Leor J, Fridrich V, Mark DB, Knatterud GL. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med, 2006, 355(23): 2395–2407.

14. Nishigaki K, Yamazaki T, Kitabatake A, Yamaguchi T, Kanmatsuse K, Kodama I, Takekoshi N, Tomoike H, Hori M, Matsuzaki M, Takeshita A, Shimbo T, Fujiwara H. Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease a randomized, comparative, multicenter study. JACC Cardiovasc Interv, 2008, 1(5): 469–479.

15. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD The Task Force on diabetes, pre-diabetes, and cardiovascular diseases oftheEuropeanSociety of Cardiology(ESC)anddeveloped incollaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J, 2015 Oct 7, 36(38): 2608-2620.

16. Hlatky МА, Boothroyd DB, Bravata DM et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet, 2009, 373: 1190–1197.

17. Frye RL, August P, Brooks MM, Hardison RM et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med, 2009, 360(24): 2503–2515.

18. Subodh Verma, Michael E Farkouh, Bobby Yanagawa et al. Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol, 2013, 1: 317—328.

19. Kappetein AP, Head SJ, Morice MC, Banning AP, Serruys PW, Mohr FW, Dawkins KD, Mack MJ, Investigators S. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg, 2013, 43(5): 1006–1013.

20. http: //www.gracescore.org/WebSite.

21. http: //www.crusadebleedingscore.org.

22. ESC guidelines on the management of stable angina pectoris. Eur Heart J, 2006 Jun, 27(11): 1341-1381.

23. Shlipak MG, Fried LF, Cushman M et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA, 2005 Apr 13, 293(14): 1737-1745.

24. National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Ann Intern Med, 2003, 139: 137- 147.

25. Chertow GM, Normand SL, McNeil BJ. «Renalism»: inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency. J Am SocNephrol, 2004, 15(9): 2462–2468.

26. Szummer K, Lundman P, Jacobson SH, Schon S, Lindback J, Stenestrand U, Wallentin L, Jernberg T. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the SwedishWeb-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). Circulation, 2009, 120(10): 851–858.

27. Hemmelgarn BR, Southern D, Culleton BF, Mitchell LB, Knudtson ML, Ghali WA. Survival after coronary revascularization among patients with kidney disease. Circulation, 2004, 110(14): 1890–1895.

28. Reddan DN, Szczech LA, Tuttle RH, Shaw LK, Jones RH, Schwab SJ, Smith MS, Califf RM, Mark DB, OwenWFJr. Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease. JAmSoc Nephrol, 2003, 14(9): 2373–2380.

29. Huang HD, Alam M, Hamzeh I, Virani S, Deswal A, Aguilar D, Rogers P, Kougias P, Birnbaum Y, Paniagua D, Kar B, Ballantyne C, Bozkurt B, Jneid H. Patients with severe chronic kidney disease benefit from early revascularization after acute coronary syndrome. Int J Cardiol, 2013, 168(4): 3741–3746.

30. Ashrith G, LeeVV, ElaydaMA, ReulRM, Wilson JM. Short— and long-term outcomes of coronary artery bypass grafting or drug-eluting stent implantation for multivessel coronary artery disease in patients with chronic kidney disease. Am J Cardiol, 2010, 106(3): 348–353.

31. Charytan DM, Li S, Liu J, Herzog CA. Risks of death and end-stage renal disease after surgical compared with percutaneous coronary revascularization in elderly patients with chronic kidney disease. Circulation, 2012, 126(11 Suppl 1): 164–169.

32. Ix JH, Mercado N, Shlipak MG, Lemos PA, Boersma E, Lindeboom W, O’Neill WW, Wijns W, Serruys PW. Association of chronic kidney disease with clinical outcomes after coronary revascularization: the Arterial Revascularization Therapies Study (ARTS). Am Heart J, 2005, 149(3): 512–519.

33. Brooks ММ, Chaitman BR, Nesto RW et al. Clinical and Angiographic Risk Stratification and Differential Impact on Treatment Outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.

34. D’Agostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, Wilson PWF, Hartz SC. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J, 2000, 139: 272–281.

35. Ranucci M, Castelvecchio S, Menicanti L, Frigiola A, Pelissero G. Risk of assessing mortality risk in elective cardiac operations: age, creatinine, ejection fraction, and the law of parsimony. Circulation, 2009, 119(24): 3053–3061.

36. Wykrzykowska JJ, Garg S, Onuma Y, de Vries T, Goedhart D, Morel MA, van Es GA, Buszman P, Linke A, Ischinger T, Klauss V, Corti R, Eberli F, WijnsW, Morice MC, diMario C, van Geuns RJ, Juni P, Windecker S, Serruys PW. Value of age, creatinine, and ejection fraction (ACEF score) in assessing risk in patients undergoing percutaneous coronary interventions in the ’All-Comers’ LEADERS trial. Circ Cardiovasc Interv, 2011, 4(1): 47–56.

37. Peterson ED, Dai D, DeLong ER, Brennan JM, Singh M, Rao SV, Shaw RE, Roe MT, Ho KK, Klein LW, Krone RJ,Weintraub WS, Brindis RG, Rumsfeld JS, Spertus JA, Participants NR. Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. J Am Coll Cardiol, 2010, 55(18): 1923–1932.

38. www.euroscore.org /calc.html.

39. Califf RM, Phillips HR 3rd, Hindman MC et al. Prognostic value of a coronary artery jeopardy score. J Am Coll Cardiol, 1985, 5: 1055–1063.

40. Ellis SG, Vandormael MG, Cowley MJ et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Circulation, 1990, 82: 1193-1202.

41. Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, van den Brand M, Van Dyck N, Russell ME, Mohr FW, Serruys PW. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention, 2005, 1(2): 219–227.

42. Levine GN, Bates ER, Blankenship JC et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol, 2011, 58: 44-122.

43. Serruys PW, Morice MC, Kappetein AP et al., for the SYNTAX Investigators. Percutaneous coronary intervention versus coronaryartery bypass grafting for severe coronary artery disease. N Engl J Med, 2009, 360: 961–972.

44. Garg S, Sarno G, Girasis C et al. A patient-level pooled analysis assessing the impact of the SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) score on 1-year clinical outcomes in 6,508 patients enrolled in contemporary coronary stent trials. J Am Coll Cardiol Interv, 2011, 4: 645–653.

45. Iijima R, Nagashima Y, Sato K, Tokue et al. SYNTAX score predicts major bleeding following drug-eluting stent implantation in an all-comers population. Rev Esp Cardiol (Engl Ed), 2015 Jan, 68(1): 54-62. doi: 10.1016/j.rec.2014.02.028. Epub 2014 Aug 22.

46. Yadav М, Palmerini Т, Caixeta А et al. Prediction of Coronary Risk by SYNTAX and Derived Scores Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery. J Am Coll Cardiol, 2013, 62: 1219–1230.

47. Farkouh ME, Domanski M, Sleeper LA et al., for the FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med, 2012, 367: 2375–2384.

48. Hochholzer W1, Trenk D, Frundi D et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation, 2005 May 24, 111(20): 2560- 2564.

49. Aradi D, Storey R F, Komocsi A et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. European Heart Journal, 2014, 35: 209–215, doi: 10.1093/eurheartj/eht375.

50. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Supplementary material. http: //eurheartj.oxfordjournals.org/content/ehj/suppl/2013/08 /23/eht375.DC1/eht375supp.pdf.

51. Tantry US., Bonello L, Aradi D, for the Working Group on On-Treatment Platelet Reactivity. Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding. J Am Coll Cardiol, 2013, 62: 2261–2273.

52. Tullio Palmerini, Paolo CalabrШ, Federico Piscione, et al. Impact of Gene Polymorphisms, Platelet Reactivity, and the SYNTAX Score on 1-Year Clinical Outcomes in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention The GEPRESS Study. J Am Coll Cardiol Intv, 2014, 7: 1117–1127.

53. Amsterdam EA, Wenger NK, Brindis RG et al. 2014 AHA/ACC guideline for the management of patients with non_ST-elevation acute coronary syndromes: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2014, 64: 139-228.

54. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, doi: 10.1093/eurheartj/ehv320.

55. Gwon HC, Hahn JY, Park KW et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation, 2012, 125: 505-513.

56. Feres F, Costa RA, Abizaid A et al. Three vs twelve months of dual antiplatelet therapy after zotarolimuseluting stents: the OPTIMIZE randomized trial. JAMA, 2013 Dec 18, 310(23): 2510-2522.

57. Kim BK, Hong MK, Shin DH et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimuseluting stent implantation). J Am Coll Cardiol, 2012 Oct 9, 60(15): 1340-1348.

58. Colombo A, Chieffo A, Frasheri A et al. Second-generation drug-eluting stent implantation followed by 6— versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol, 2014 Nov 18, 64(20): 2086-2097.

59. Navarese EP, Andreotti F, Schulze V et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ, 2015, 350: doi:10.1136/bmj.h1618.

60. Giustino G, Baber U, Sartori S, Mehran R, Mastoris I, Kini AS, Sharma SK, Pocock SJ, Dangas GD, Duration of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Journal of the American College of Cardiology, 2015, doi: 10.1016/j.jacc.2015.01.039.

61. Udell JA, Bonaca MP, Collet JP et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative metaanalysis of randomized trials. Eur Heart J, 2016 Jan 21, 37(4): 390-399.

62. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O’Gara PT, Sabatine MS, Smith PK, Smith Jr SC, Focused Update Writing Group, 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease, Journal of the American College of Cardiology, 2016) doi: 10.1016/j.jacc.2016.03.513.

63. Yeh RW, Secemsky E, Kereiakes DJ et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond one year after percutaneous coronary intervention: an analysis from the randomized Dual Antiplatelet Therapy Study. JAMA, 2016 Apr 26, 315(16): 1735-49.

64. www.daptstudy.org.

65. Laura Mauri, Dean J. Kereiakes, Robert W. Yeh et al. Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. N Engl J Med, 2014, 371: 2155-2166.

66. Camenzind E, WijnsW, Mauri L et al. Stent thrombosis and major clinical events at 3 years after zotarolimuseluting or sirolimus-eluting coronary stent implantation. Lancet, 2012, 380(9851): 1396-1405.


Для цитирования:


Комаров А.Л., Московкина Е.С. СОВРЕМЕННЫЕ ПОДХОДЫ К СТРАТИФИКАЦИИ РИСКА БОЛЬНЫХ, ПОДВЕРГАЕМЫХ ПЛАНОВЫМ ЧРЕСКОЖНЫМ КОРОНАРНЫМ ВМЕШАТЕЛЬСТВАМ. Атеротромбоз. 2016;(2):65-80. https://doi.org/10.21518/2307-1109-2016-2-65-80

For citation:


., . . Atherothrombosis. 2016;(2):65-80. (In Russ.) https://doi.org/10.21518/2307-1109-2016-2-65-80

Просмотров: 217


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2307-1109 (Print)
ISSN 2658-5952 (Online)